HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre.

Abstract
Clinical and serological records of 865 patients with confirmed autoimmune haemolysis (AIH)--a much larger series than any previously reported--were critically reviewed nd analysed. A proposed new classification for AIH based on serological findings differs from traditional classifications in that a new category of "mixed" AIH has been defined in which both "warm" and "cold" autoantibodies are present, and both are capable of causing haemolysis. Patients in this mixed group tend to have severe disease that may run a chronic intermittent course. The presentation of cold agglutinin disease is much more variable than has been seen in previous studies, haemolysis due to low titre autoantibodies being common. The AIH associated with pregnancy, usually considered as being of bad prognosis, is often mild and self limiting in the absence of other associated disorders.
AuthorsR J Sokol, S Hewitt, B K Stamps
JournalBritish medical journal (Clinical research ed.) (Br Med J (Clin Res Ed)) Vol. 282 Issue 6281 Pg. 2023-7 (Jun 20 1981) ISSN: 0267-0623 [Print] England
PMID6788179 (Publication Type: Journal Article)
Chemical References
  • Autoantibodies
  • Methyldopa
Topics
  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Anemia, Hemolytic, Autoimmune (chemically induced, classification, immunology)
  • Antibody Specificity
  • Autoantibodies (analysis)
  • Child
  • Child, Preschool
  • Cold Temperature
  • Coombs Test
  • Female
  • Hemoglobinuria, Paroxysmal (immunology)
  • Humans
  • Infant
  • Male
  • Methyldopa (adverse effects)
  • Middle Aged
  • Pregnancy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: